6 Feb 2019 I Financial Statement Release for 2018 and related materials now published.
The 2019 Annual General Meeting will be held on 26 March 2019 in Helsinki. Registration closes on 20 March. Instructions and registration link can be found on these pages.
|2/6/2019||The Board of Directors of Orion Corporation decided on an incentive plan for key persons|
|2/6/2019||Notice to the Annual General Meeting of Orion Corporation|
|2/6/2019||Orion Group Financial Statement Release for 2018|
|1/9/2019||Recommendation by the Nomination Committee concerning Board of Directors to be elected by the 2019 AGM of Orion Corporation|
|2/14/2019||Orion's and Bayer's darolutamide shows substantial efficacy and a favourable safety profile in the treatment of prostate cancer in the ARAMIS trial|
|2/11/2019||Orion and Propeller Health partner to bring new digital medicines to people with asthma and COPD|
|2/5/2019||Orion and Bayer jointly present new data in prostate cancer from the Darolutamide ARAMIS -study|
|2/4/2019||Orion intents to start an open label extension study to the REFALS phase 3 trial studying the effect of oral levosimendan in patients with ALS|
Information about the price development of Orion's A and B shares. Also available a list of analysts covering Orion and the latest consensus estimate.
Orion's key research projects include three ongoing Phase III trials, among others.
The Closing of the transaction took place on 30 April 2018.
Orion Corporation has been included in the globally recognised FTSE4Good Index.